Can you get medical cannabis for Crohn's disease?

Crohn's is the condition where the gap between feeling better and being better is at its most consequential. Inflammation that is not controlled causes damage whether or not the symptoms have quietened down.

Is Crohn's disease assessed for medical cannabis?

Yes, privately, and usually for symptom burden rather than for the disease itself. No cannabis-based product is licensed for Crohn's disease, and NICE guidance on its management does not include them.

This page covers Crohn's specifically. The broader picture, including ulcerative colitis, is in medical cannabis for inflammatory bowel disease, and the distinct question of IBS is in medical cannabis for irritable bowel syndrome.

What the evidence actually shows

The Cochrane review is the reference point, and its conclusion was negative for remission. The individual trials it examined were small, short, and reported improvement in how people felt rather than in measured inflammation.

The most-cited individual study randomised a small number of patients with active Crohn's to smoked cannabis or placebo and reported improvement in symptom scores. Inflammatory markers did not change correspondingly. That pattern — symptoms better, inflammation unchanged — has repeated across the small studies since.

A reasonable reading is that cannabis-based medicines may help some people feel better without treating the disease process. That is not worthless, and it is not remission. It is also worth being clear about what the evidence cannot tell you: the trials were too small and too short to show whether any symptom benefit lasts, who is most likely to respond, or how it compares with adjusting your existing treatment. Those are the questions your specialist has to weigh case by case, on your history rather than on an average.

Why that distinction matters so much in Crohn's

Because Crohn's causes cumulative structural damage — strictures, fistulas and the operations that follow — and that damage tracks inflammation rather than symptoms.

Someone whose symptoms are masked while inflammation continues can feel reasonably well while the disease progresses. This is the specific risk a gastroenterologist is thinking about, and it is why symptom improvement alone does not reassure them.

It is also why any use alongside Crohn's treatment belongs inside gastroenterology follow-up, with the monitoring that normally involves, rather than as a private arrangement your IBD team does not know about.

What a specialist will want to see

The disease-modifying treatments you have had, what happened with each, and what your current disease activity actually is on objective measures rather than on how you feel.

• Your diagnosis, disease location and behaviour, and how long you have had it
• Which therapies you have tried, and whether each failed, was not tolerated, or was stopped for another reason
• Recent inflammatory markers, faecal calprotectin, imaging or endoscopy
• Previous surgery, strictures or fistulas
• Whether your IBD team knows you are considering this
• Smoking, which independently worsens Crohn's disease

That last point is worth stating plainly: smoking is one of the clearest modifiable risk factors in Crohn's, and inhaling any smoked material sits badly with that. See vaporising versus smoking.

The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?

Risks and reasons a specialist may say no

The general cautions apply, and two specific ones carry extra weight in inflammatory bowel disease.

The first is masking. A treatment that improves symptoms without improving inflammation can delay a change of therapy that was needed. The second is displacement: people occasionally reduce or stop an immunosuppressant or biologic because they feel better, which is the sequence that leads to hospital admissions.

Stopping or reducing Crohn's therapy is a decision for the team that prescribed it, and nothing on this page is a reason to do it.

How medical cannabis is thought to help

The honest answer is that the mechanism in Crohn's is not fully understood. The general idea is that the body has an endocannabinoid system — receptors and signalling molecules found throughout the nervous system and the gut — that is involved in pain signalling, gut motility, appetite and inflammation, and that the cannabinoids in cannabis interact with it.

THC and CBD act on that system in different ways, which is why products are described by their balance of the two rather than as a single medicine. In the gut, cannabinoid receptors are present in the lining and in the nerves that supply it, which offers a plausible route by which symptoms such as pain, cramping and urgency might ease. What the trials show, though, is that any such effect has so far been on how people feel rather than on the inflammation itself — so a plausible mechanism is not the same as a proven benefit. If you want the underlying biology, see the endocannabinoid system explained and THC and CBD explained.

What treatment involves in practice

If a specialist decides a supervised trial is reasonable, treatment follows a consistent pattern: start low, go slow, and review. The starting point is deliberately cautious, and the dose is adjusted gradually according to how you respond and what side effects appear.

The usual formats are oils or capsules taken by mouth and dried flower for vaporising. Oils are steady and easy to measure; vaporised flower acts faster but wears off sooner, which suits different needs. Your specialist chooses the format and the balance of cannabinoids with you, and there is no single dose that fits everyone — how a dose is set and changed is covered in how a dose is decided and adjusted, and the formats themselves in how cannabis-based medicines are taken.

Follow-up reviews are where the real decisions are made. The specialist checks whether symptoms have genuinely improved, whether side effects are tolerable, and — importantly in Crohn's — that your objective disease markers are still being monitored by your IBD team. Treatment that is not helping enough is stopped rather than continued out of habit. How quickly any effect appears varies, and is discussed in how long cannabis medicines take to work; the common unwanted effects are set out in side effects of cannabis-based medicines.

Living with treatment day to day

A prescription for a cannabis-based medicine carries some practical responsibilities that are worth understanding before you start, particularly around driving, work and travel.

• Driving. THC-containing products can impair driving, and you must never drive while impaired. There is a medical defence for driving on a prescribed medicine taken as directed — see driving with a medical cannabis prescription.
• Work and testing. A workplace drug test can detect THC, and it helps to know where you stand in advance: medical cannabis, drug testing and work.
• Travel. Taking a prescribed cannabis-based medicine abroad is not straightforward and depends on the destination country's own law: travelling abroad with a prescription.
• Your GP. Telling your GP keeps your record complete and your care joined up: telling your GP.

If you want to take this further

The useful next step is a proper assessment, not a longer reading list. Gather your diagnosis, the treatments you have already tried and what happened with each, and a current list of your medicines — that is what a specialist needs in order to give you a straight answer.

The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If Crohn's disease is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.

Patient guide · Written by the Flora House editorial team · Last reviewed: 7 October 2026